SLC38A5 Promotes Glutamine Metabolism and Inhibits Cisplatin Chemosensitivity in Breast Cancer

Overview

Journal Breast Cancer

Specialty Oncology

Date 2023 Nov 2

PMID 37914960

Authors

Xiaowei Shen

Ganggang Wang

Hua He

Ping Shang

Bin Yan

Xiaoliang Wang

Weixing Shen

Affiliations

Soon will be listed here.

Abstract

Background: Solute carrier family 38 member 5 (SLC38A5), as an amino acid transporter, play a vital role in cellular biological processes. In this study, we analyzed the function of SLC38A5 and its potential mechanism in breast cancer (BC) progression.

Methods: The expression of SLC38A5 in cancer and adjacent-normal tissues was analyzed by qRT-PCR and Western blot, and its correlation with patient prognosis was analyzed. The immunohistochemical staining of cancer tissues and adjacent-normal tissues was performed on SLC38A5-positive specimens. BC mice were successfully applied to examine the role of SLC38A5 on tumor proliferation using the CCK-8 assay. In BC cells and mouse tumor tissues, SLC38A5 and PCNA expression were determined by Western blotting.

Results: The study found that SLC38A5 was highly expressed in BC patients and associated with a poor survival. SLC38A5 silencing inhibited BC cell viability and glutamine uptake. In addition, SLC38A5 overexpression promoted BC cell viability via the glutamine metabolism. SLC38A5 inhibited cisplatin chemosensitivity in BC cells. Importantly, SLC38A5 silencing inhibited tumor growth in vivo.

Conclusion: Our findings suggest that SLC38A5 enhances BC cell viability by glutamine metabolism, inhibits the chemical sensitivity of cisplatin in BC cells, and promotes tumor growth, emphasizing the clinical relevance of SLC38A5 in BC management as a novel potential therapeutic target.

Citing Articles

Identification of the shared gene signatures in retinoblastoma and osteosarcoma by machine learning.

Ye R, Yuan Q, You W, Huang Y, Lin Z, Tang H Sci Rep. 2024; 14(1):31355.

PMID: 39733097 PMC: 11682156. DOI: 10.1038/s41598-024-82789-7.

SLC38A5 suppresses ferroptosis through glutamine-mediated activation of the PI3K/AKT/mTOR signaling in osteosarcoma.

Huang X, Xia K, Wei Z, Liu W, Wei Z, Guo W J Transl Med. 2024; 22(1):1004.

PMID: 39511570 PMC: 11542360. DOI: 10.1186/s12967-024-05803-6.

Impact of Oncogenic Changes in p53 and KRAS on Macropinocytosis and Ferroptosis in Colon Cancer Cells and Anticancer Efficacy of Niclosamide with Differential Effects on These Two Processes.

Nguyen N, Sennoune S, Dharmalingam-Nandagopal G, Sivaprakasam S, Bhutia Y, Ganapathy V Cells. 2024; 13(11.

PMID: 38891084 PMC: 11171492. DOI: 10.3390/cells13110951.

Oxidative Stress in Breast Cancer: A Biochemical Map of Reactive Oxygen Species Production.

Belskaya L, Dyachenko E Curr Issues Mol Biol. 2024; 46(5):4646-4687.

PMID: 38785550 PMC: 11120394. DOI: 10.3390/cimb46050282.

A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle.

Wang B, Pei J, Xu S, Liu J, Yu J J Exp Clin Cancer Res. 2024; 43(1):74.

PMID: 38459595 PMC: 10921613. DOI: 10.1186/s13046-024-02994-0.

References

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Sharma R . Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990-2019: an examination using estimates from the global burden of disease 2019 study. Breast Cancer Res Treat. 2023; 202(3):529-540. DOI: 10.1007/s10549-023-07075-y. View

Feng H, Li W, Zhang Y, Chang C, Hua L, Feng Y . Mechanistic modelling of relative biological effectiveness of carbon ion beams and comparison with experiments. Phys Med Biol. 2023; 69(3). DOI: 10.1088/1361-6560/ad1998. View

Thakur P, Dahiya H, Kaushal A, Gupta V, Saini A, Saini R . Exosomal miRNAs as Next-generation Therapy Vehicles in Breast Cancer. Curr Gene Ther. 2023; 23(5):330-342. DOI: 10.2174/1566523223666230215103524. View

Cluntun A, Lukey M, Cerione R, Locasale J . Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends Cancer. 2017; 3(3):169-180. PMC: 5383348. DOI: 10.1016/j.trecan.2017.01.005. View

Anderson P, Lalla R . Glutamine for Amelioration of Radiation and Chemotherapy Associated Mucositis during Cancer Therapy. Nutrients. 2020; 12(6). PMC: 7352314. DOI: 10.3390/nu12061675. View

Li T, Le A . Glutamine Metabolism in Cancer. Adv Exp Med Biol. 2018; 1063:13-32. DOI: 10.1007/978-3-319-77736-8_2. View

Yang W, Qiu Y, Stamatatos O, Janowitz T, Lukey M . Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy. Trends Cancer. 2021; 7(8):790-804. PMC: 9064286. DOI: 10.1016/j.trecan.2021.04.003. View

You S, Han X, Xu Y, Yao Q . Research progress on the role of cationic amino acid transporter (CAT) family members in malignant tumors and immune microenvironment. Amino Acids. 2023; 55(10):1213-1222. DOI: 10.1007/s00726-023-03313-1. View

10.

Bhutia Y, Ganapathy V . Glutamine transporters in mammalian cells and their functions in physiology and cancer. Biochim Biophys Acta. 2016; 1863(10):2531-9. PMC: 4919214. DOI: 10.1016/j.bbamcr.2015.12.017. View

11.

Ramachandran S, Sennoune S, Sharma M, Thangaraju M, Suresh V, Sneigowski T . Expression and function of SLC38A5, an amino acid-coupled Na+/H+ exchanger, in triple-negative breast cancer and its relevance to macropinocytosis. Biochem J. 2021; 478(21):3957-3976. PMC: 8652584. DOI: 10.1042/BCJ20210585. View

12.

Sniegowski T, Korac K, Bhutia Y, Ganapathy V . SLC6A14 and SLC38A5 Drive the Glutaminolysis and Serine-Glycine-One-Carbon Pathways in Cancer. Pharmaceuticals (Basel). 2021; 14(3). PMC: 8000594. DOI: 10.3390/ph14030216. View

13.

Guidi N, Longo V . Periodic fasting starves cisplatin-resistant cancers to death. EMBO J. 2018; 37(14). PMC: 6043846. DOI: 10.15252/embj.201899815. View

14.

Girardi E, Cesar-Razquin A, Lindinger S, Papakostas K, Konecka J, Hemmerich J . A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. Nat Chem Biol. 2020; 16(4):469-478. PMC: 7610918. DOI: 10.1038/s41589-020-0483-3. View

15.

Gote V, Nookala A, Bolla P, Pal D . Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue. Int J Mol Sci. 2021; 22(9). PMC: 8125767. DOI: 10.3390/ijms22094673. View

16.

Garcia-Martinez L, Zhang Y, Nakata Y, Chan H, Morey L . Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021; 12(1):1786. PMC: 7979820. DOI: 10.1038/s41467-021-22024-3. View

17.

Dong X, Bai X, Ni J, Zhang H, Duan W, Graham P . Exosomes and breast cancer drug resistance. Cell Death Dis. 2020; 11(11):987. PMC: 7673022. DOI: 10.1038/s41419-020-03189-z. View

18.

Nedeljkovic M, Damjanovic A . Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019; 8(9). PMC: 6770896. DOI: 10.3390/cells8090957. View

19.

Yoo H, Yu Y, Sung Y, Han J . Glutamine reliance in cell metabolism. Exp Mol Med. 2020; 52(9):1496-1516. PMC: 8080614. DOI: 10.1038/s12276-020-00504-8. View

20.

Li T, Copeland C, Le A . Glutamine Metabolism in Cancer. Adv Exp Med Biol. 2021; 1311:17-38. PMC: 9703266. DOI: 10.1007/978-3-030-65768-0_2. View